



Protherics PLC
3 Creed Court
5 Ludgate Hill
London EC4M 7AA UK
Tel: +44 (0)20 7246 9950
Fax: +44 (0)20 7329 5924

Dr Daniel Brasseur
European Medicines Agency
7 Westferry Circus
Canary Wharf
London E14 4HB

21 May 2007

**Withdrawal of Voraxaze powder for solution for injection 1000 Units (glucarpidase)
EMEA/H/C/681**

Dear Dr Brasseur

This is to advise that Protherics PLC has taken the decision to withdraw the Marketing Authorisation application for Voraxaze (glucarpidase) for use in the adjunctive treatment of patients experiencing or at risk of methotrexate toxicity. The reason for the withdrawal is that it will not be possible to provide the additional data requested in the time frame required by the Centralised Procedure.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

We agree for this letter to be published on the EMEA website.

Yours sincerely

cc Dr T Salmonsson - MPA
Dr I Hudson - MHRA
Dr F Pignatti - EMEA

NORTH AMERICA
PROTHERICS INC
EUROPE
PROTHERICS LTD
ASIA/PACIFIC
PROTHERICS PTE LTD

EUROPE
PROTHERICS LTD
ASIA/PACIFIC
PROTHERICS PTE LTD

ASIA/PACIFIC
PROTHERICS PTE LTD

WWW.PROTHERICS.COM